Shenwei Pharmaceutical Gains 4.9% on 13.1% Profit Growth

Edgen Stock

·Mar 27 2026, 06:36

Share to

Share to

Copy link

Key Takeaways

Shenwei Pharmaceutical (02877.HK) announced robust 2025 full-year results, where a significant increase in profitability overshadowed a decline in sales. The market responded positively, pushing the stock higher on the news of strong earnings and a commitment to shareholder returns through a new dividend.

Contrasting Performance: The company reported a 13.1% year-over-year increase in net profit to RMB950 million, despite a 17% decrease in revenue to RMB3.135 billion.
Positive Market Reaction: Investors embraced the news, driving the stock up 4.86% to HKD9.06 on March 27, with shares reaching an intraday peak of HKD9.08.
Shareholder Payout: Shenwei declared a first interim dividend of RMB0.43 per share for 2026, signaling confidence and bringing the total 2025 fiscal year payout to RMB0.54 per share.

Stock Climbs 4.86% as Profit Growth Outweighs Revenue Dip

Shenwei Pharmaceutical's stock (02877.HK) gained 4.86% to HKD9.06 on March 27 after the company announced its full-year 2025 financial results. Investors focused on a 13.1% year-over-year increase in net profit, which reached RMB950 million, and largely disregarded a 17% drop in revenue to RMB3.135 billion. Earnings per share for the period stood at RMB1.26.

The market's bullish reaction was swift, with the stock's gains expanding throughout the afternoon session to a peak of HKD9.08. The move was backed by a trading volume of 460,000 shares, representing capital flows of approximately HKD4.1 million. The positive sentiment suggests investors are prioritizing profitability and efficiency over top-line growth alone.

Dividend and Efficiency Signal Management Confidence

The company's ability to expand its bottom line during a period of falling sales indicates a successful focus on higher-margin products or effective cost management measures. This operational efficiency provides a strong foundation for shareholder returns, which the company underscored by declaring a first interim dividend for 2026 of RMB0.43 per share.

This new dividend, combined with the second interim dividend for 2025 of RMB0.11 per share, brings the total payout for the fiscal year to RMB0.54 per share. This represents a dividend payout ratio of 42.9%, a tangible commitment to returning capital to shareholders that signals management's confidence in the firm's future financial stability and earnings power.